Abstract | INTRODUCTION: AREAS COVERED: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients. EXPERT OPINION: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.
|
Authors | Erika Rijavec, Federica Biello, Carlo Genova, Giulia Barletta, Claudia Maggioni, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Irene Vanni, Angela Alama, Sabrina Beltramini, Maria Attilia Grassi, Francesco Boccardo, Francesco Grossi |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 15
Issue 9
Pg. 1371-9
( 2015)
ISSN: 1744-7682 [Electronic] England |
PMID | 26211534
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antigens, Neoplasm
- Cancer Vaccines
- Transforming Growth Factor beta2
- belagenpumatucel L
|
Topics |
- Antigens, Neoplasm
(immunology)
- Cancer Vaccines
(immunology, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(immunology, pathology, therapy)
- Clinical Trials as Topic
- Humans
- Immunotherapy
- Lung Neoplasms
(immunology, pathology, therapy)
- Transforming Growth Factor beta2
(antagonists & inhibitors, genetics)
|